Frailty, Sarcopenia, and Hormones

• Autores: John E. Morley, Theodore K. Malmstrom
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 42, Nº. 2, 2013 (Ejemplar dedicado a: Aging and Endocrinology), págs. 391-405
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Frailty is now a definable clinical syndrome with a simple screening test. Age-related changes in hormones play a major role in the development of frailty by reducing muscle mass and strength (sarcopenia). Selective Androgen Receptor Molecules and ghrelin agonists are being developed to treat sarcopenia. The role of Activin Type IIB soluble receptors and Follistatin-like 3 mimetics is less certain because of side effects. Exercise (resistance and aerobic), vitamin D and protein supplementation, and reduction of polypharmacy are keys to the treatment of frailty.